Neo Ivy Capital Management Exelixis, Inc. Transaction History

Neo Ivy Capital Management

$293 Million
Q1 2025

A detailed history of Neo Ivy Capital Management transactions in Exelixis, Inc. stock. As of the latest transaction made, Neo Ivy Capital Management holds 28,056 shares of EXEL stock, worth $1.11 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares

28,056

Previous 53,892 47.94%

Holding current value

$1.11 Million

Previous $1.79 Million 42.31%

% of portfolio

0.35%

Previous 0.36%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 06, 2025	SELL	$32.38 - $39.16 $836,569 - $1.01 Million	-25,836 Reduced 47.94%	28,056 $1.04 Million
Q4 2024 Feb 18, 2025	BUY	$25.39 - $36.46 $1.11 Million - $1.59 Million	43,682 Added 427.84%	53,892 $1.79 Million
Q3 2024 Nov 15, 2024	BUY	$21.96 - $27.6 $224,211 - $281,796	10,210 New	10,210 $264,000
Q2 2023 Aug 15, 2023	BUY	$18.17 - $20.48 $483,830 - $545,341	26,628 New	26,628 $508,000
Q3 2022 Nov 15, 2022	BUY	$15.68 - $22.27 $215,756 - $306,435	13,760 Added 4845.07%	14,044 $220,000
Q2 2022 Aug 16, 2022	BUY	$17.44 - $23.16 $4,952 - $6,577	284 New	284 $5,000
Q4 2021 Feb 15, 2022	SELL	$15.84 - $21.88 $348 - $481	-22 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$16.3 - $21.14 $673,613 - $873,631	-41,326 Reduced 99.95%	22 $1,000
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $742,196 - $1.06 Million	41,348 New	41,348 $753,000
Q1 2021 Oct 07, 2021	SELL	$20.53 - $25.22 $157,095 - $192,983	-7,652 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $5,884 - $7,936	-320 Reduced 4.01%	7,652 $154,000
Q3 2020 Nov 17, 2020	BUY	$20.67 - $26.94 $164,781 - $214,765	7,972 New	7,972 $194,000
Q2 2020 Aug 17, 2020	SELL	$16.46 - $27.42 $362 - $603	-22 Closed	0 $0
Q2 2020 Aug 17, 2020	SELL	$16.46 - $27.42 $11,884 - $19,797	-722 Reduced 97.04%	22 $1,000
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $82,667 - $124,630	-5,717 Reduced 88.48%	744 $13,000
Q4 2019 Feb 13, 2020	SELL	$15.15 - $18.89 $391,248 - $487,834	-25,825 Reduced 79.99%	6,461 $114,000
Q3 2019 Nov 21, 2019	BUY	$17.68 - $22.65 $570,816 - $731,277	32,286 New	32,286 $641,000
Q2 2019 Aug 15, 2019	SELL	$18.93 - $24.75 $2,877 - $3,762	-152 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $2,979 - $3,763	152 New	152 $3,000

Others Institutions Holding EXEL

# of Institutions

684

Shares Held

260M

Call Options Held

1.41M

Put Options Held

1.55M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $12.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Neo Ivy Capital Management with notifications on news.

Account

Neo Ivy Capital Management Exelixis, Inc. Transaction History